

DAFTAR PUSTAKA

1. Sugondo S. Obesitas. *Ilmu Penyakit Dalam*. Jakarta: Interna Publishing. 2015; 6(2): 2561-2571.
2. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman Tatalaksana Sindrom Koroner Akut Edisi Ketiga. Centra Communications. 2015.
3. Karamat Muhammad A, Raja Umar Y, Manley Susan E, et al. Prevalence of undiagnosed type 2 diabetes in patients admitted with acute coronary syndrome the utility of easily reproducible screening methods. *BioMed Central Endo Dis*. 2017; 17(3):1-8.
4. Caccamo G, Bonura F, Vitale G, et al. Insulin resistance and acute coronary syndrome. *Atherosclerosis*. 2010; 211(2):672-675.
5. Soegondo S & Purnamasari D. Sindrom Metabolik. *Ilmu Penyakit Dalam*. Jakarta: Interna Publishing. 2015; 6(2): 2537-2538.
6. Wilcox G. Insulin and Insulin Resistance. *Clin Biochem Rev*. 2005; 26(2): 19-39.
7. Bermudez V, Salazar J, Martinez M, et al. Prevalence and associated factors of insulin resistance in adults from Maracaibo City, Venezuela. *Adv in Prev Med*. 2016; 9405105:1-13.
8. Misra A, Khurana L, Isharwal S, et al. South Asian diets and insulin resistance. *British J of Nutr*. 2009;101(4): 465-473.
9. Soewondo P, Purnamasari D, Oemardi M, et al. Prevalence of metabolic syndrome using NCEP/ATP III criteria in Jakarta Indonesia : The Jakarta primary non-communicable disease risk factors surveillance 2006. *Acta Med Indones J Intern Med*. 2010; 42(4):199-203.



10. Thaane T, Motala A, Mckune A. Lifestyle modification in the management of insulin resistance states in overweight/obesity: the role of exercise training. *J Endocrinol Metab Diabetes South Africa*. 2019;24(2):65-69.
11. Bloomgarden Z. The sixth annual world congress on the insulin resistance syndrome. *Diabetes Care*. 2009; 32(11): e127-133.
12. Gutch M, Kumar S, Razi Syed M, et al. Assesment of insulin sensitivity resistance. *Indian J of Endocrin and Metab*. 2015; 19(1):160-165.
13. Suoza A, Batista Batista G, Alegre S. Assesment of insulin sensitivity by the hyperinsulinemic euglycemic clamp: Comparisaon with the spectral analysis of photoplethysmography. *J of Diabet and Its comp*.2017. 31;128-133.
14. Horakova D, Stepanek L, Janout V, et al. Optimal Homeostasis Model Assesment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross Sectional Study in the Czech Population. *Medicina*. 2019;55(5):158.
15. Refaie W, Elewa A. Admission insulin resistance index in non diabetic patients with acute coronary syndrome clinical and angiographic features. *The Egypt Heart J*. 2013; 65:301-305.
16. Stubbs PJ, Zadeh A, Laycock J, et al. Significance of an index of insulins resistance on admission in non-diabetic patients with acute coronary syndrome. *Heart*.1999; 82:443-447.
17. Fu Zhou, Gilbert E, Liu D. Regulation of insulin synthesis and secretion and pancreatic beta cell dysfunction in diabetes. *Current Diabetes Rev*. 2013;9(1):25-53.
18. Tokarz V, MacDonald P, Klip A. The cell biology of systemic insulin function. *J of Cell Bio*. 2018;217(7):2273-2289.

19. Qaid M & Abdelrahman M. Role of insulin and other related hormones in energy metabolism a review. *Cog Food and Agri.* 2016; 2: 1267691.
20. Pettersen K, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. *Proc of the National Acad of Sci.* 2006;103(48):18273-18277.
21. Reaven G. Role of insulin resistance in human disease. *Diabetes.* 1988; 37:1595-1607.
22. Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and development of cardiovascular disease. *Cardiovasc Diabetol.* 2018;17:122
23. Johnson A & OLefsky J. The origins and drivers of insulin resistance. *Cell.* 2013;152(4): 673-684.
24. Peterson K & Shulman G. Etiology of insulin resistance. *Am J Med.* 2006;199(5 Suppl 1):S10-S16.
25. Duan Y, Zeng L, Zheng C, et al. Inflammatory links between high fat diets and disease. *Front in Imunol.*2018;13(9):2649.
26. Ginsberg H. Insulin resistance and cardiovascular disease. *The Journal of Clin Invest.* 2000; 106(4):453-458.
27. Lewis G & Steiner G. Acute effects of insulin in the control of VLDL production in humans:implications for the insulin resistant state. *Diabetes Care.* 1996; 19(4): 390-393.
28. Malhotra A, Kang B, Cheung, et al. Angiotensin II promotes glucose induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. *Diabetes.* 2001;50(8):1918-1926.

29. Morse S, Zhang R, Thakur V, et al. Hypertension and the metabolic syndrome. *Am J Med Sci.* 2005; 330(6): 303-310.
30. Rizwejik L, Rutger W, Meer VD, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. *J Am Coll of Cardiol.* 2008; 52(22):1793-1799.
31. Howard G, O'Leary D, Zacaro D, et al. Insulin sensitivity and atherosclerosis. *Circulation.* 1996; 93(10):1809-1817.
32. Facchini F, Hua N, Abbasi F, et al. Insulin resistance as a predictor of age-related disease. *The Journal of Clin Endo and Metab.* 2001. 86(8): 3574-3578.
33. Tenenbaum A, Adler Y, Boyko V, et al. Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease. *Am Heart J.* 2007; 153 (4):559-565.
34. Park YW, Zhu S, Palaniappan L, et al. The Metabolic syndrome : Prevalence and associated risk factors findings in the US Population from the Third National Health and Nutrition Examination Survey. *Arch Intern Med.* 2003;163: 427-435.
35. Scherrer U, Randin D, Vollenweider P, et al. Nitric Oxide release accounts for insulin's vascular effects in humans. *J Clin Invest.* 1994;94(6):2511-2515.
36. DeFronso RA. Insulin Resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. *Diabetologia.*2010;53(7):1270-1287.
37. Reaven G. Metabolic Syndrome: Pathophysiology and implications for management of cardiovascular disease. *Circulation.* 2002;106(3):286-288.
38. Karowni W, Li Y, Jones P, et al. Insulin resistance is associated with significant clinical atherosclerosis in non diabetic patients with acute myocardial infarction. *Arterioscler Thromb Vasc Biol.* 2013;33: 2245-2251.

39. Qatanani M & Lazar MA. Mechanisms of obesity-associated insulin resistance: Many choice on the menu. *Genes Dev.*2007;21(12): 1443-55.
40. Nyambuya TM, Dludla PV, Mixinwa V, et al. Obesity-induced inflammation and insulin resistance: A mini review on T cells. *Metab Open.*2019;3 :100015
41. Peterson MD, Al Snih S, Serra-Rexach JA, et al. Android adiposity and lack of moderate and vigorous physical activity are associated with insulin resistance and diabetes in aging adults. *J Gerontol A Biol Sci Med Sci.* 2015;70(8):1009-17.
42. Balducci S, D' Errico V, Haxhi J, et al. Level and correlates of physical activity and sedentary behavior in patients with type 2 diabetes : A cross-sectional analysis of the Italian Diabetes and Exercise study 2. *PLOS One.*2017;12(3):1-15
43. Dirks ML, Wall BT, Van De Valk B, et al. One week of bed rest leads to substantial muscle atrophy and induced whole-body insulin resistance in the absence of skeletal muscle lipid accumulation. *Diab.*2016;65(10):2862-75.
44. Amano SU, Cohen JL, Vangala P,et al. Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. *Cell Metab.*2014;19(1):162-71.
45. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest.*2003; 112 (12):1821-30.

Lampiran

| | | | | |
|--|---|--|--|---|
|  | KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN KESEHATAN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431 | | |  |
| <u>REKOMENDASI PERSETUJUAN ETIK</u> Nomor : 1155/UN4.6.4.5.31/ PP36/ 2019 | | | | |
| Tanggal: 29 Nopember 2019 | | | | |
| Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik : | | | | |
| No Protokol | UH19100886 | | No Sponsor Protokol | |
| Peneliti Utama | dr. Resy Rosalina | | Sponsor | |
| Judul Peneliti | Hubungan Kluster Metabolik Dengan Admission Insulin Resistance Index (AIRI) Pada Pasien Sindrom Koroner Akut Non Diabetes Melitus | | | |
| No Versi Protokol | 1 | | Tanggal Versi | 23 Oktober 2019 |
| No Versi PSP | 1 | | Tanggal Versi | 23 Oktober 2019 |
| Tempat Penelitian | RSUP dr. Wahidin Sudirohusodo Makassar | | | |
| Jenis Review | <input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal | | Masa Berlaku 29 Nopember 2019 sampai 29 Nopember 2020 | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FKUH | Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K) | | Tanda tangan  | |
| Sekretaris Komisi Etik Penelitian Kesehatan FKUH | Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K) | | Tanda tangan  | |
| Kewajiban Peneliti Utama: <ul style="list-style-type: none"> Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah Menyerahkan laporan akhir setelah Penelitian berakhir Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation) Mematuhi semua peraturan yang ditentukan | | | | |